| Literature DB >> 32327202 |
Hua Su1, Ming Yang2, Cheng Wan1, Li-Xia Yi1, Fang Tang1, Hong-Yan Zhu1, Fan Yi3, Hai-Chun Yang4, Agnes B Fogo4, Xiu Nie5, Chun Zhang6.
Abstract
Although the respiratory and immune systems are the major targets of Coronavirus Disease 2019 (COVID-19), acute kidney injury and proteinuria have also been observed. Currently, detailed pathologic examination of kidney damage in critically ill patients with COVID-19 has been lacking. To help define this we analyzed kidney abnormalities in 26 autopsies of patients with COVID-19 by light microscopy, ultrastructural observation and immunostaining. Patients were on average 69 years (19 male and 7 female) with respiratory failure associated with multiple organ dysfunction syndrome as the cause of death. Nine of the 26 showed clinical signs of kidney injury that included increased serum creatinine and/or new-onset proteinuria. By light microscopy, diffuse proximal tubule injury with the loss of brush border, non-isometric vacuolar degeneration, and even frank necrosis was observed. Occasional hemosiderin granules and pigmented casts were identified. There were prominent erythrocyte aggregates obstructing the lumen of capillaries without platelet or fibrinoid material. Evidence of vasculitis, interstitial inflammation or hemorrhage was absent. Electron microscopic examination showed clusters of coronavirus-like particles with distinctive spikes in the tubular epithelium and podocytes. Furthermore, the receptor of SARS-CoV-2, ACE2 was found to be upregulated in patients with COVID-19, and immunostaining with SARS-CoV nucleoprotein antibody was positive in tubules. In addition to the direct virulence of SARS-CoV-2, factors contributing to acute kidney injury included systemic hypoxia, abnormal coagulation, and possible drug or hyperventilation-relevant rhabdomyolysis. Thus, our studies provide direct evidence of the invasion of SARSCoV-2 into kidney tissue. These findings will greatly add to the current understanding of SARS-CoV-2 infection.Entities:
Keywords: COVID-19; SARS-CoV-2; acute kidney injury; proteinuria; renal pathology
Mesh:
Year: 2020 PMID: 32327202 PMCID: PMC7194105 DOI: 10.1016/j.kint.2020.04.003
Source DB: PubMed Journal: Kidney Int ISSN: 0085-2538 Impact factor: 10.612
Clinical information of 26 patients with COVID-19
| ID | Sex | Age (y) | History of HT, DM, CKD or tumor | Hypotension/vasopressor | BUN (mmol/l) | Cr (μmol/l) | Urine | Hb (g/l) | WBC (g/l) | LY (g/l) | LY% | PLT (T/l) | D-dimer (μg/ml) | ALT (U/l) | AST (U/l) | TBIL (μmol/l) | CK (U/l) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRO | BLD | WBC | |||||||||||||||||
| 1 | M | 77 | N | Y | 22.52 | 239.8 | N/A | N/A | N/A | N/A | 25.1 | 0.37 | 1.50 | 33 | >8.00 | 60 | 71 | N/A | N/A |
| 2 | F | 60 | N | N | N/A | N/A | − | 2+ | 1+ | 112 | 17.87 | 0.82 | 4.60 | 103 | 2.35 | N/A | N/A | N/A | N/A |
| 3 | M | 51 | Pancreas Ca | Y | 18.96 | 71.3 | Trace | − | − | 96 | 31.87 | 0.75 | 2.40 | 38 | 5.61 | 102 | 126 | 110.2 | 328 |
| 4 | M | 87 | DM, HT, CKD | Y | 42.45 | 229.8 | N/A | N/A | N/A | 70 | 13.63 | 0.26 | 1.90 | 219 | 1.08 | 13 | 16 | 9.5 | 99 |
| 5 | M | 39 | Gastric Ca | N | 7.18 | 31 | N/A | N/A | N/A | 98 | 11.4 | 0.44 | 3.90 | 273 | 6.1 | 15 | 18 | 23.9 | 87 |
| 6 | M | 66 | Liver Ca | Y | 41.84 | 161.4 | N/A | N/A | N/A | 89 | 12.52 | 0.24 | 1.90 | 57 | 0.9 | 184 | 150 | 49.1 | 1001 |
| 7 | M | 77 | Skin Ca | Y | 24.14 | 460.2 | N/A | N/A | N/A | 93 | 23.59 | 0.81 | 3.40 | 105 | 5.32 | 21 | 48 | 13.6 | 312 |
| 8 | F | 87 | DM, HT, CKD | Y | N/A | N/A | 3+ | 3+ | 1+ | 101 | 8.98 | 0.48 | 5.40 | 110 | >8.00 | N/A | N/A | N/A | N/A |
| 9 | M | 70 | Lung Ca | N | 12.86 | 207.3 | N/A | N/A | N/A | 112 | 5.76 | 0.81 | 14.10 | 215 | 2.85 | 367 | 840 | 14.9 | 2459 |
| 10 | F | 84 | HT | N | 14.28 | 114.7 | N/A | N/A | N/A | 60 | 7.69 | 0.53 | 6.80 | 75 | 2.86 | 29 | 30 | 16.1 | 54 |
| 11 | F | 83 | HT | Y | 21.54 | 108 | N/A | N/A | N/A | 69 | 2.28 | 0.17 | 7.30 | 30 | 2.08 | 717 | 954 | 6.5 | 495 |
| 12 | M | 63 | HT | Y | 7.3 | 45.9 | − | ± | − | 102 | 41.48 | 0.53 | 1.30 | 179 | 1.02 | 107 | 44 | 8.5 | 158 |
| 13 | M | 52 | N | Y | 7.51 | 58.7 | 2+ | − | ± | 73 | 11.19 | 0.66 | 5.90 | 342 | 2.69 | 97 | 52 | 18.9 | 194 |
| 14 | M | 61 | HT | Y | 13.99 | 94.2 | 1+ | 1+ | ± | 80 | 15.67 | 0.64 | 4.10 | 80 | 2.3 | 88 | 77 | 41.3 | 259 |
| 15 | F | 70 | HT, Lung Ca | Y | 5.79 | 44.1 | N/A | N/A | N/A | 102 | 18.89 | 1.21 | 6.40 | 106 | >8.00 | 54 | 35 | 26.1 | 37 |
| 16 | M | 64 | HT | Y | 20.42 | 137.3 | N/A | N/A | N/A | 93 | 3.35 | 0.56 | 16.80 | 23 | 7.69 | 21 | 38 | 18.9 | 64 |
| 17 | M | 66 | HT | Y | 3.24 | 57.9 | 2+ | 3+ | 1+ | 81 | 0.26 | 0.08 | 29.90 | 15 | 4.95 | 349 | 157 | 3.2 | N/A |
| 18 | F | 62 | N | Y | 11.86 | 61.8 | N/A | N/A | N/A | 88 | 9.14 | 0.69 | 7.60 | 76 | 3.42 | 19 | 18 | 14.2 | 23 |
| 19 | M | 55 | DM, HT | Y | 9.24 | 43.7 | 2+ | 1+ | 3+ | 78 | 1.28 | 0.08 | 6.20 | 18 | 2.05 | 599 | 1199 | 57.7 | 34 |
| 20 | M | 83 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 21 | F | 86 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 22 | M | 78 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 23 | M | 62 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 24 | M | 51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 25 | M | 72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 26 | M | 86 | HT | Y | 4.36 | 63.6 | 1+ | − | − | 97 | 45.44 | 0.38 | 0.80 | 155 | 3.77 | 15 | 35 | 24.5 | 213 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BLD, blood; BUN, blood urea nitrogen; Ca, cancer; CK, creatine kinase; CKD, chronic kidney disease; Cr, creatinine; DM, diabetes; F, female; Hb, hemoglobin; HT, hypertension; ID, identification number; LY, lymphocytes; M, male; N, no; N/A, not available; PLT, platelet; PRO, proteinuria; TBIL, total bilirubin; WBC, white blood cell; Y, yes.
The cause of death in all patients was respiratory failure. In addition, patients 1, 5, 14, 15, 16, 25, and 26 had multiorgan failure.
Treatment history
| ID | Exposure to nephrotoxic drug | Renal replacement therapy | Antivirals | Steroid |
|---|---|---|---|---|
| 1 | N | N | Arbidol | Y |
| 2 | Y | CRRT | Arbidol | Y |
| 3 | N | N | Ribavirin | N |
| 4 | N | N | Ribavirin, arbidol | N |
| 5 | N | N | Arbidol | Y |
| 6 | N | N | Arbidol | Y |
| 7 | N | CRRT | Arbidol | Y |
| 8 | N | N | Arbidol | N |
| 9 | N | N | N | N |
| 10 | N | CRRT | Arbidol | Y |
| 11 | N | N | Arbidol | Y |
| 12 | N | N | Arbidol | Y |
| 13 | Y | N | Lopinavir/ritonavir | Y |
| 14 | Y | N | N | Y |
| 15 | N | N | Lopinavir/ritonavir | Y |
| 16 | N | N | Lopinavir/ritonavir | Y |
| 17 | Y | N | N | Y |
| 18 | N | CRRT | N | Y |
| 19 | N | CRRT | Lopinavir/ritonavir | Y |
| 20 | N/A | N/A | N/A | N/A |
| 21 | N/A | N/A | N/A | N/A |
| 22 | N/A | N/A | N/A | N/A |
| 23 | N/A | N/A | N/A | N/A |
| 24 | N/A | N/A | N/A | N/A |
| 25 | N/A | N/A | N/A | N/A |
| 26 | N | N | Lopinavir/ritonavir | Y |
CRRT, continuous renal replacement therapy; ID, identification number; N, no; N/A, not available; Y, yes.
Figure 1Spectrum of pathologic abnormalities of kidneys from postmortems of patients with coronavirus disease 2019. (a,b) Proximal tubules showed (a) loss of brush border and (b) vacuolar degeneration (arrows), with debris composed of necrotic epithelium in tubular lumens (asterisks). Erythrocyte aggregates obstructing peritubular capillaries were frequently present (arrowheads). (c,d) Some cases showed infiltration of inflammatory cells in (c) tubules and (d) in 1 case, in an arcuate artery (arrows), with multiple foci of bacteria (asterisks) and white blood cell casts (arrowhead). (e,f) Occasional (e) hemosiderin granules and (f) deposits of calcium (arrowheads) were present in tubules with occasional pigmented casts (arrows). (g,h) Segmental fibrin thrombi were present in glomeruli (arrowhead), with ischemic glomerular contraction (arrows) with the accumulation of leaked plasma in Bowman’s space (asterisks). Hematoxylin and eosin. Bars = (f) 50 μm, (a–c,e,g,h) 100 μm, and (d) 250 μm. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
The pathologic abnormalities of kidney in 26 cases of deceased patients with COVID-19
| ID | LM | EM | IF | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tubule interstitium | Glomeruli | |||||||||||
| ATI | Multiple foci of bacteria | Pigmented casts | Arteriosclerosis | Segmental fibrin thrombus | FSGS | Coronavirus-like particles | Dense deposits | Subendothelial lucent expansion | IgG | IgA | SARS-CoV NP | |
| 1 | Severe | N | N | Mild to moderate | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 2 | Moderate | N | N | Mild | N | N | Y | N | N | N/A | N/A | N/A |
| 3 | Mild to moderate | N | Y | Mild | N | N | Y | N | Y | N/A | N/A | N/A |
| 4 | Severe | N | N | Severe | N | Y | Y | N | Y | N/A | N/A | N/A |
| 5 | Mild | N | N | Mild | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 6 | Mild to moderate | N | Y | Mild | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 7 | Severe | N | N | Mild to moderate | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 8 | Moderate | N | N | Severe | Focal | Y | N/A | N/A | N/A | N/A | N/A | N/A |
| 9 | Moderate | N | Y | Moderate | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 10 | Moderate | N | N | Moderate to severe | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 11 | Moderate to severe | N | N | Moderate to severe | Focal | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 12 | Moderate to severe | N | N | Moderate | N | N | Y | N | Y | N/A | N/A | N/A |
| 13 | Mild to moderate | N | N | Mild | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 14 | Severe | Multiple focal | N | Moderate | Diffuse | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 15 | Mild to moderate | N | N | Moderate to severe | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 16 | Severe | Multiple focal | N | Moderate to severe | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 17 | Moderate | N | N | Moderate | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 18 | Moderate | N | N | Mild | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 19 | Mild | N | N | Moderate to severe | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
| 20 | Moderate to severe | N | N | Moderate | N | N | Y | N | N | N | N | N |
| 21 | Mild | N | N | Moderate to severe | N | N | N | Y | Y | Y | N | N |
| 22 | Moderate | N | N | Mild to moderate | N | N | Y | N | N | N | N | Y |
| 23 | Moderate | N | N | Moderate | N | N | N | N | N | N | N | Y |
| 24 | Mild | N | N | Mild | N | N | N/A | N/A | N/A | N | N | N |
| 25 | Moderate to severe | N | N | Moderate to severe | N | N | Y | Y | Y | N | Y | Y |
| 26 | Mild to moderate | N | N | Mild | N | N | N/A | N/A | N/A | N/A | N/A | N/A |
ATI, acute tubular injury; COVID-19, coronavirus disease 2019; EM, electron microscopy; FSGS, focal segmental glomerulosclerosis; ID, identification number; IF, immunofluorescent (stain); LM, light microscopy; N, not detected; N/A, not available; NP, nucleoprotein; SARS-CoV, severe acute respirator syndrome coronavirus; Y, detected.
Figure 2Ultrastructural features of kidneys from postmortems of patients with coronavirus disease 2019. (a–d) Coronavirus-like particles (red arrowheads) with distinctive spikes (green arrowheads) were present in the cytoplasm of (a) the proximal and (b) distal tubular epithelium. (c,d) Coronavirus-like particles (red arrowheads) with distinctive spikes (green arrowheads) were present in podocytes; foot processes of podocytes (arrow); glomerular basement membrane (star). (e) A single case of IgA nephropathy was diagnosed by immunofluorescent staining with a few paramesangial and subendothelial electron-dense deposits (asterisks) with marked subendothelial lucent expansion (arrow) and mesangial interposition (arrowhead). (f) Peritubular capillary with stasis of red blood cells (arrow) and activation or injury of endothelial cells (arrowhead). Transmission electron microscopy. Bars = (a–d) 200 nm, (e) 1 μm, and (f) 5 μm. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
Figure 3Immunostaining of paraffin-embedded kidney tissue from patients with coronavirus disease 2019 (COVID-19). (a) Serial sections stained for CD235, CD61, and CD31 showing stasis of red blood cells without platelets in peritubular capillaries. Bars = 100 μm. (b,c) Angiotensin-converting enzyme II (ACE2) stained mainly proximal tubules in (b) non–coronavirus disease 2019 case, with (c) strong proximal tubular staining and parietal epithelial cell staining with occasional weak podocyte staining in some COVID-19 cases. (d) Indirect immunofluorescent staining with anti–severe acute respirator syndrome coronavirus (SARS-CoV) nucleoprotein antibody. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.